Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualised first line chemotherapy in metastatic colorectal cancer (mCRC)
2011-005495-42Phase 2
Key facts
- Status
- Terminated
- Start
- Apr 2012
- Countries
- 1
- Sponsor
- Kincell Bio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Conditions
- metastatic colon cancer (mCRC)Colon carcinoma (CC)rectal cancerhepatic metastasis
01
Overview
Phase 2 trial of capecitabine, oxaliplatin, irinotecan and bevacizumab in metastatic colon cancer (mCRC), Colon carcinoma (CC), rectal cancer and 1 more, sponsored by Kincell Bio. Primary endpoint: Progression-free survival. Started Apr 2012; status: terminated.
02
Who it enrols
Adults with histologically confirmed colon or rectal cancer with metastases, receiving first-line chemotherapy and without any prior chemotherapy exposure, including adjuvant therapy.
03
Endpoints
Primary
Progression-free survival
Secondary
Plasma TIMP-1 sequence
Additional biomarker changes
Beyond the preview
Go deeper on 2011-005495-42.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005495-42.